08th week of 2011 patent applcation highlights part 38 |
Patent application number | Title | Published |
20110044929 | FORMULATIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES - The present inventors have developed a novel composition and method for inhibiting inflammation and treating of symptoms of tissue ischemia, including that associated with peripheral and cardiac vascular disease by local administration of a pharmaceutical composition including an effective amount of a poloxamer. | 2011-02-24 |
20110044930 | COPOLYHYDROXYALKYLGLUTAMINES FUNCTIONALISED WITH HYDROPHOBIC GROUPS, AND USES THEREOF, ESPECIALLY IN THERAPEUTICS - The invention relates to novel biodegradable materials which are based on modified polyamino acids and which can be used for the vectorisation of active principle(s) (AP). The invention also relates to novel pharmaceutical, cosmetic, dietary or phytosanitary compositions based on said polyamino acids. The aim of the invention is to provide a novel polymer raw material which can be used for the vectorisation of active principles and which can optimally fulfil all required specifications in said area, namely: biocompatibility, biodegradability and the ability to become easily associated with many active principles or to solubilise said principles and to release same in vivo. Said aim is achieved with novel copolyhydroxyalkylglutamines comprising glutamine units and optionally glutamate units and bearing hydrophobic groups containing between 8 and 30 carbon atoms. Said copolyhydroxyalkylglutamines are amphiphilic and can be easily and economically transformed into particles for the vectorisation of active principles, whereby said particles can form stable aqueous colloidal suspensions. | 2011-02-24 |
20110044931 | MULTI-CONJUGATE OF SIRNA AND PREPARING METHOD THEREOF - The present invention relates to a multi-conjugate of small interfering RNA (siRNA) and a preparing method of the same, more precisely a multi-conjugate of siRNA prepared by direct binding of double stranded sense/antisense siRNA monomers or indirect covalent bonding mediated by a cross-linking agent or a polymer, and a preparing method of the same. The preparing method of a siRNA multi-conjugate of the present invention is characterized by simple and efficient reaction and thereby the prepared siRNA multi-conjugate of the present invention has high molecular weight multiple times the conventional siRNA, so that it has high negative charge density, suggesting that it has excellent ionic interaction with a cationic gene carrier and high gene delivery efficiency. | 2011-02-24 |
20110044932 | Crosslinked Polyalkyleneimine Hydrogels with Tunable Degradation Rates - One aspect of the present invention relates to methods of sealing a wound or tissue plane or filling a void space, or securing meshes, films or other devices within the body. In certain embodiments, the wound is an ophthalmic, pleural or dural wound, or a hernia repair mesh. Remarkably, disclosed herein is the discovery that the use of certain crosslinkers in combination with polyalkyleneimines at specific concentrations can result in hydrogels with tunable degradation properties. | 2011-02-24 |
20110044933 | PARTICLES, OBTAINED BY DRYING AN AQUEOUS NANOUREA DISPERSION - The present invention relates to particles produced by drying aqueous dispersions of nanoureas and to methods for the production thereof. | 2011-02-24 |
20110044934 | TEXTILES TREATED WITH COPOLYMERS OF EPOXY COMPOUNDS AND AMINO SILANES - The present invention provides for treating textiles with a composition comprising the reaction product of a) an oxirane or oxetane compound comprising at least two oxirane or oxetane groups; and b) an amino silane having the formula: N(H)(R | 2011-02-24 |
20110044935 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CARDIOMYOPATHY AND HEART DISEASE - The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188-P188) and methods of using the same for treating and preventing heart disease (e.g., in subjects with muscular dystrophy) and for treating cells and tissue damage caused by ischemia and cell death (e.g., for treating dystrophin-deficient cells (e.g., myocytes)). | 2011-02-24 |
20110044936 | Composition for Attracting Bed Bugs - The present invention provides a composition comprising an unsaturated aldehyde component and an organic acid component which is a powerful bed bug attractant when volatilized and released at very low concentrations. This attractant can be used to lure bed bugs to a location in which the bed bugs can be detected, monitored and/or trapped. | 2011-02-24 |
20110044937 | STAGED IMMUNE-RESPONSE MODULATION IN ONCOLYTIC THERAPY - The invention provides methods for treating tumours, such as solid tumours, in a host. The methods may involve infecting the tumour with an amount of one or more strains of oncolytic virus. The virus will generally be selected to be effective to cause a lytic infection of tumour cells within the tumour. In various embodiments, the host neutrophil response to the lytic infection may be modulated, so that during the course of the lytic infection, the host has an initial neutrophil response and a secondary neutrophil response, these two responses being different in some material respect. For example, the secondary neutrophil response may mediate a greater degree of apoptotic killing of tumour cells than does the initial neutrophil response. | 2011-02-24 |
20110044938 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES - Compounds of a certain formula I, in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity. | 2011-02-24 |
20110044939 | REGULATORY T CELLS IN ADIPOSE TISSUE - Methods of preventing, delaying, or reducing the development or severity of obesity-associated disorders, including administering Fat-specific regulatory T cells, or administering factors secreted by said T cells. | 2011-02-24 |
20110044940 | Thiazole Carboxamide Derivatives and Their Use to Treat Cancer - The present invention relates to novel Heterocyclic Ether or Thioether Derivatives, compositions comprising the Heterocyclic Ether or Thioether Derivatives, and methods for using the Heterocyclic Ether or Thioether Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection, a fungal infection, or a disorder related to the activity of a protein kinase. | 2011-02-24 |
20110044941 | IMMUNOTHERAPY FOR REVERSING IMMUNE SUPPRESSION - A method for overcoming immune suppression includes the steps of inducing production of naïve T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T cells and exposing the naïve T cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is administered in combination with thymosin α | 2011-02-24 |
20110044942 | METHODS OF TREATMENT FOR SOLID TUMORS - The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula I, | 2011-02-24 |
20110044943 | Anti-Viral Compounds, Compositions, And Methods Of Use - Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses. | 2011-02-24 |
20110044944 | ANTI-INFLAMMATORY COMPOSITIONS FOR TREATING BRAIN INFLAMMATION - Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biochemicals from the activated mast cells, the compositions containing one or more of a flavone or flavonoid glycoside a heavily sulfated, non-bovine proteoglycan, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, a hexosamine sulfate such as D-glucosamine sulfate, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRR, a long-chain unsaturated fatty acid, a phospholipid, Krill oil, a polyamine, glutiramer acetate and interferon. Certain of the present compositions are useful in protecting against the neuropathological components of multiple sclerosis and similar inflammatory neurological diseases. | 2011-02-24 |
20110044945 | AGENTS FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND METHODS OF USING SAME - A method of treating Multiple Sclerosis is disclosed. The method comprises administering to the subject a therapeutically effective amount of SDF-1 alpha. An article of manufacture comprising SDF-1 alpha and an anti-Multiple Sclerosis agent is also disclosed. | 2011-02-24 |
20110044946 | GENETEC REGULATION OF HOST DEFENSE MECHANISMS BY MUCOSAL EXPOSURE TO NATURAL INTERFERON ALPHA SPECIES - A mixture of α-interferons (IFN-α) is used in vitro or in vivo as an antimicrobial agent or anticancer agent. It may be administered by topical application to oral or nasal, and/or buccal mucosa to combat the effects of infection by bacteria or protozoa, cancer, or other pathogenic disease process (e.g., autoimmune or neurodegenerative disease). | 2011-02-24 |
20110044947 | METHODS OF TREATING CARDIAC DISORDERS - The invention feature methods and compositions for treating ischemic and reperfusuin related injury such as cardiac disorders. | 2011-02-24 |
20110044948 | POXVIRAL ONCOLYTIC VECTORS - A poxvirus comprising a defective F2L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer. | 2011-02-24 |
20110044949 | ONCOLYTIC VIRUS REPLICATING SELECTIVELY IN TUMOR CELLS - By using a virus having a gene sequence comprising a telomerase promoter and an E1 gene (preferably a sequence comprising E1A gene, IRES sequence and E1B gene) or by using an anticancer agent comprising the virus, the virus replicates in cancer cells to thereby produce an efficient anticancer effect. | 2011-02-24 |
20110044950 | Infusion of a Mixture of Autologous Bone Marrow-Derived Mononuclear Cells and Autologous or Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Treating Myocardial and/or Cardiovascular Disorders - The present invention is a method for improving cardiac and/or cardiovascular functions in living subjects after the occurrence of a myocardial and/or cardiovascular disorder, involving tissue damage and/or an ischemic event. The method is a combination stem cell therapy involving a mixture of bone marrow-derived mesenchymal stem cells and bone marrow-derived mononuclear cells surgically implanted by using either a direct or catheter-mediated injection into damaged tissue. Studies have shown that the implant improves blood perfusion in an ischemic tissue and thus contributes to the recovery of cardiac and/or cardiovascular function as assessed by methods of choice, including magnetic resonance imaging (“MRI”), echocardiography, angiography and 99mTc-TF perfusion scintigraphy. | 2011-02-24 |
20110044951 | COMPOSITIONS FOR PREPARING A COFFEE BEVERAGE COMPRISING HYDROLYSED CHLOROGENIC ACID - The invention relates to compositions for preparing a beverage, the compositions comprise a microorganism and/or an enzyme capable of hydrolysing chlorogenic acids of a coffee extract to phenolic acids. When a beverage prepared with the compositions of the invention is consumed chlorogenic acids present in coffee extract is hydrolysed to improve antioxidant and/or anti-inflammatory properties compared to a similar conventional beverage. | 2011-02-24 |
20110044952 | AMPLIFICATION OF CANCER-SPECIFIC ONCOLYTIC VIRAL INFECTION BY HISTONE DEACETYLASE INHIBITORS - The invention provides methods for treating cancer cells in a host by infecting the cancer cells with one or more strains of oncolytic virus, in conjunction with treating the host with an amount of an HDI that is effective to augment the cancer-cell-specific oncolytic infection. | 2011-02-24 |
20110044953 | Methods and Compositions for Localized Secretion of Anti-CTLA-4 Antibodies - The present invention provides compositions and methods for effectuating the localized expression of anti-CTLA-4 antibody proximal to a target tissue in a patient. | 2011-02-24 |
20110044954 | Methods of producing germ-like cells and related therapies - The present invention relates to methods of producing germ-like cells (GLCs) from embryonic stem cells and induced pluripotent stem cells, GLCs produced by such methods, gametes derived from such GLCs, pharmaceutical compositions and kits containing such GLCs, screens that use GLCs to identify agents useful in enhancing mammalian reproductive health, and methods of treatment that use GLCs to enhance mammalian reproductive health. | 2011-02-24 |
20110044955 | ALTERING MEMORY BY AFFECTING STAUFEN - The present invention provides cell-based screening methods for identifying pharmaceutical agents which are capable of modulating (have the ability to modulate) STAUFEN function by screening for STAUFEN function. | 2011-02-24 |
20110044956 | NELL-1 ENHANCED BONE MINERALIZATION - This invention pertains to the discovery that the human NELL-1 gene induces or upregulates bone mineralization. The NELL-1 gene or gene product thus provides a convenient target for screening for modulators of bone mineralization. In addition, NELL-1 can be used to facilitate repair of bone fractures and/or to generally increase bone density. | 2011-02-24 |
20110044957 | METHODS AND SYSTEMS FOR EXTENDED IN VITRO CULTURE OF NEURONAL CELLS - A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided. | 2011-02-24 |
20110044958 | ACTIVATED MESENCHYMAL STEM CELLS FOR THE PREVENTION AND REPAIR OF INFLAMMATORY STATES - Inflammatory cytokines e.g. IFN-γ serve as initiating stimuli for MSC immunosuppressive activity in vivo. Other inflammatory cytokines, such as TNF alpha, the molecule hemoxygenase I, and TLR ligation of MSC may also provide such a response. | 2011-02-24 |
20110044959 | NOVEL COMPOSITION OF STEM CELLS FOR TRANSPLANTATION TOLERANCE - The present invention provides a simple, economical yet efficient method of creating transplant tolerance in organ transplant patients without the continuous need for costly immunosuppressive drugs with serious adverse effects. The invention essentially deals with the administration of a novel composition to the patient which consists of adipose tissue derived Mesenchymal Stem Cells (MSC) combined with bone marrow derived Haematopoietic Stem Cells(HSC) and MSC and peripheral blood stem cells (PBSC). This helps in creating transplant tolerance ie. Stable adequate allograft function with minimum/no rejection using very low dose of immunosuppressive medication. The invention also deals with a simple method of isolating Mesenchymal Stem cells from human adipose tissue without using any xenogenic material. | 2011-02-24 |
20110044960 | MEDICAMENT, DENTAL MATERIAL, AND METHOD OF SCREENING - The present invention provides a novel and creative dental materials for treatment of pulpitis and/or enhancement of dentinogenesis. The dental materials of the present invention contain at least one of a protein having matrix metalloprotease 3 activities or matrix metalloprotease 3 precursor protein as an active ingredient. The dental materials of the present invention contain a carrier having biocompatibility. The dental materials of the present invention can contain at least one cell type among pulp cells, pulp stem cells, pulp progenitor cells, odontoblasts or cells that can differentiate into odontoblasts. | 2011-02-24 |
20110044961 | Generation of Induced Pluripotent Stem Cells from Cord Blood - Methods and compositions for the generation and use of genetically corrected induced pluripotent stem cells are provided. | 2011-02-24 |
20110044962 | NOTCH INDUCED NATURAL KILLER CELL GENERATION AND THERAPEUTIC USES - A method of preparing differentiated NK cells by ex vivo expansion includes the steps of; (1) isolating a plurality of CD34 | 2011-02-24 |
20110044963 | Method of Testing a Patient for Hypertension and Related Method of Treatment and Test Kit - A method of testing a patient for hypertension includes providing a urine specimen from the patient, performing a first test on the urine specimen to determine if volume expansion hypertension exists by measuring the level of marinobufagenin in the urine specimen, performing a second test on the urine specimen to determine if vasoconstrictive hypertension exists by measuring the level of angiotensinogen in the urine specimen, and performing the first and second tests on the urine specimen substantially simultaneously without either test having an adverse effect on the other test. The tests may employ a test strip having a first region for use in the first test and a second region for use in the second test with each region effecting a visible change if the condition for which the test is being formed is found to exist. A related method of treatment and a related test kit are also disclosed. | 2011-02-24 |
20110044964 | PLANT-BASED OMEGA CHEWABLE SUPPLEMENT - A chewable composition for the oral delivery of plant-based omega fatty acid compounds. The chewable composition includes a delivery vehicle and an active ingredient incorporated therein. The delivery vehicle may include an organic or in-organic gummy candy made from a binding agent, sweeteners, flavoring, and coloring. The active ingredient may include a plant-based omega fatty acid to provide a desired effect on the user. The delivery vehicle may also include any combination of nutraceuticals, vitamins, minerals, antioxidants, soluble and insoluble fiber, herbs, plants, probiotics, prebiotics, antioxidants, amino acids, digestive enzymes, proprietary dietary supplements, or any other health promoting ingredient. | 2011-02-24 |
20110044966 | USE OF A SUBSTANCE FOR MANUFACTURING OF A MEDICAMENT FOR TREATMENT OF COMMON COLD - A method for treatment and/or prevention of common cold caused by rhinovirus, wherein a patient in need is treated with a medicament including a hydrogen peroxide producing enzyme. | 2011-02-24 |
20110044967 | Conjugates Comprising a Biodegradable Polymer and Uses Therefor - Biologically active agents covalently linked to a polymer. The polymer is preferably a biodegradable polymer are provided. The biologically active agent is preferably a protein, such as an extracellular soluble protein, e.g., an extracellular enzyme. The enzyme can be an apyrase, e.g., NTPDase. Conjugates of the invention can be used as therapeutics in subjects. For example, a conjugate comprising an apyrase can be used for treating and preventing thrombosis, atherosclerotic plaque complications and vascular disorders. | 2011-02-24 |
20110044968 | COMPOSITIONS FOR TREATMENT WITH METALLOPEPTIDASES, METHODS OF MAKING AND USING THE SAME - The present invention is directed to biocompatible compositions and the use of metal bridges to connect a back-bone and a metallopeptidase active agent. In certain instances, the subject compositions provide a means of achieving sustained release of the metallopeptidase active agent after administration to a subject. | 2011-02-24 |
20110044969 | Antimicrobial Agents for the Treatment of Campylobacter Species in the Crop of a Bird - The invention provides an antimicrobial agent for use in the treatment of a | 2011-02-24 |
20110044970 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DRY EYE - The invention generally relates to methods and compositions for treating dry eye and related conditions by administering compositions comprising compounds that increase capillary permeability of either the lacrimal gland, accessory lacrimal gland, or ocular surface. | 2011-02-24 |
20110044971 | METHOD AND COMPOSITION FOR TREATING A SERATONIN RECEPTOR-MEDIATED CONDITION - A method and composition for treating serotonin receptor-mediated conditions. | 2011-02-24 |
20110044972 | PROCESS FOR PREPARING NUTRITIONAL, THERAPEUTIC OR ORGANOLEPTIC PRODUCTS FROM CRUDE GLYCEROL - The present invention relates to a process for preparing a nutritional, therapeutic or organoleptic product by growing non-recombinant yeast under aerobic conditions, in a medium that includes crude glycerol, as one possible carbon source to produce a yeast product. The yeast product can be processed to obtain such nutritional, therapeutic or organoleptic products as yeast paste, yeast metabolites, carbohydrates, proteins, functional proteins, nucleotides, yeast autolysates, yeast extract, yeast cell walls, beta-glucans, mannans or a product derived from a mineralized yeast product. | 2011-02-24 |
20110044973 | TREATMENT OF CYSTIC DISEASE WITH LYSOPHOSPHATIDIC ACID ANTAGONISTS - A method for treating cystic diseases is disclosed herein. The method comprises administering lysophosphatidic acid receptor antagonists. | 2011-02-24 |
20110044974 | Peptide analogues comprising at least one type of aminoacylaza-$g(b)<sp>3</sp>and the use thereof, in particular for therapy - The object of the present invention is analogues of peptides or parent proteins, these peptide analogues, comprising at least one aza-β | 2011-02-24 |
20110044975 | TREATMENT OF PRION PROTEIN RELATED DISEASES - According to the present invention, treatment of prion protein related diseases, and in particular cancer tumours, is effected by providing to a subject in need thereof a therapeutically effective amount of an agent capable of modulating binding of a prion protein and/or a prion-like protein to a disease related GAG and/or HSPG. | 2011-02-24 |
20110044976 | HUMANIZED ANTIBODIES - Humanized antibodies that bind ICAM-1 are provided. Antibodies include those selected from: SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID NO:25 and 27 (HumG); SEQ ID NO:29 and 31 (HumH); and SEQ ID NO:33 and 35 (HumI). Subsequences of the humanized antibodies capable of binding an ICAM-1 epitope are also provided. Methods of inhibiting pathogen infection (e.g., HRV) of a cell employing humanized antibodies capable of binding an ICAM-1 epitope are further provided. | 2011-02-24 |
20110044977 | Subcutaneous anti-HER2 antibody formulations and uses thereof - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 2011-02-24 |
20110044978 | METHOD FOR TREATING BONE FRACTURE - The invention provides a method of enhancing bone fracture healing involving administering a sclerostin inhibitor. In one aspect, the invention includes use of a therapeutically effective amount of sclerostin binding agent to treat a bone fracture, wherein one or more administrations of the sclerostin binding agent are administered over a treatment period lasting at least two weeks and beginning within two weeks of the fracture. | 2011-02-24 |
20110044979 | DOMAIN ANTIBODY CONSTRUCT - The present invention provides a domain antibody construct which binds to human TNF-α, with the construct comprising:
| 2011-02-24 |
20110044980 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2011-02-24 |
20110044981 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROTIC DISORDERS - Disclosed herein are methods and compositions for preventing and treating pulmonary fibrotic disorders, and for reducing or reversing the symptoms of pulmonary fibrotic disorders, such as idiopathic pulmonary fibrosis. The compositions include inhibitors of the LOXL2 protein, and the methods include methods for making and using the inhibitors. | 2011-02-24 |
20110044982 | MULTIFUNCTIONAL LINKER PROTEIN CONTAINING AN ANTIBODY AGAINST HEMAGGLUTININ, A CONSERVED INFLUENZA ANTIGEN AND AN IMMUNOSTIMULATING CARRIER BINDING DOMAIN - The invention relates to the field of immunology and vaccines. In particular, it relates to proteinaceous substances and the uses thereof in vaccines against infections caused by respiratory pathogens. | 2011-02-24 |
20110044983 | COMPLEMENT INHIBITORS AS THERAPEUTIC AGENTS FOR TREATMENT OF CANCER - Methods for treating, preventing or delaying onset of tumor formation and other forms of cancer are disclosed. The methods involve administration of a complement inhibitor to inhibit C5a receptor signaling in the tumor microenvironment. | 2011-02-24 |
20110044984 | Monoclonal Antibody Capable of Binding to Anexelekto, and Use Thereof - The present inventors have succeeded in producing anti-AXL antibodies with specific functions. The present inventors also discovered that the antibodies have an angiogenesis-suppressive effect and an antitumor effect, and thereby completed the present invention. The anti-AXL antibodies of the present invention are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity. | 2011-02-24 |
20110044985 | ANTIBODIES DIRECTED AGAINST AMYLOID-BETA PEPTIDE AND METHODS USING SAME - Methods of using antibodies directed to the C-terminal side of β-amyloid peptide for diagnosing and treatment of Alzheimer's disease and Aβ peptide associated diseases are described. | 2011-02-24 |
20110044986 | ANTI-AMYLOID ANTIBODIES AND USES THEREOF - Compositions for treating neurodegenerative or amyloidogenic disorders such as Alzheimer's disease (AD) are provided. More particularly, anti-amyloid-beta antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided. | 2011-02-24 |
20110044987 | MONOCLONAL ANTIBODIES AND BINDING FRAGMENTS THEREOF DIRECTED TO THE MELANOCORTIN-4 RECEPTOR AND THEIR USE IN THE TREATMENT OF CACHEXIA AND RELATED CONDITIONS AND DISEASES - Disclosed are monoclonal antibodies, binding fragments, and derivatives thereof directed to the human melanocortin-4 receptor, as well as pharmaceutical compositions including the same, and therapeutic uses, including methods for treating cachexia and related conditions and diseases, using such monoclonal antibodies, binding fragments, derivatives, and pharmaceutical compositions. | 2011-02-24 |
20110044988 | METHODS OF TREATMENT USING ANTI-MIF ANTIBODIES - Disclosed herein, in certain embodiments, is a method for treating an inflammatory disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding to CXCR2 and CXCR4 and/or (ii) MIF-activation of CXCR2 and CXCR4; (iii) the ability of MIF to form a homomultimer; or a combination thereof. | 2011-02-24 |
20110044989 | Zona Pellucida Binding Peptides, Expression Vectors, Compositions, and Methods for Species Specific Immunocontraception of Animals - Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines. | 2011-02-24 |
20110044990 | ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES - The present invention provides crystalline forms of an anti-lipid antibody or fragment thereof, which may further comprise a lipid ligand of said antibody and/or salts, metals, or co-factors. Methods for making such crystals and co-crystals are provided. The lipid may be a bioactive lipid, including sphingolipids such as S1P. X-ray coordinates of such a crystal are provided, as are methods of using this information in antibody design or optimization. Methods for designing a humanized antibody to a lipid are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided. | 2011-02-24 |
20110044991 | METHODS AND COMPOSITIONS FOR TREATING LYMPHOMA AND MYELOMA - This invention relates to the use of antagonists of the hedgehog signaling pathway to induce apoptosis of lymphoma and myeloma cells and to treat subjects suffering from various forms of lymphoma or myeloma. | 2011-02-24 |
20110044992 | METHOD OF DELIVERING AN ANTI-CANCER AGENT TO A CELL - There is provided a delivery vehicle comprising an anti-cancer agent together with a conjugate of a delivery agent containing a free aldehyde and a flavonoid, having the delivery agent conjugated at the C6 and/or the C8 position of the A ring of the flavonoid. The resulting delivery vehicles may be used to deliver an anti-cancer agent to a cell. | 2011-02-24 |
20110044993 | METHOD FOR THE PREVENTION AND TREATMENT OF CANCER BY INHIBITION OF GPVI - The invention provides an inhibitor of GPVI for the prevention and or therapy of cancer and also the use of such an inhibitor of GPVI in the manufacture of a medicament for the prevention and/or therapy of cancer. A further aspect of the invention are pharmaceutical formulations comprising a GPVI inhibitor, which are suitable for the treatment of cancer, preferably for skin cancer, more preferably for melanoma, and most preferably for malignant cutaneous melanoma. | 2011-02-24 |
20110044994 | HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES - The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided. | 2011-02-24 |
20110044995 | ANTI-HIV MONOCLONAL ANTIBODY - The present invention provides a monoclonal antibody that recognizes the V3 loop of the envelope glycoprotein gp120 of AIDS virus, which is any one selected from the following antibodies:
| 2011-02-24 |
20110044996 | NEUTRALIZING ANTIBODIES - The present invention provides antibodies that bind, interact or otherwise associate with GM-CSF or a fragment, portion or part thereof and antagonize or neutralize GM-CSF activity. In accordance with embodiments of the present invention humanized monoclonal antibodies are generated which bind to human GM-CSF with high affinity and which inhibit the activity of GM-CSF. | 2011-02-24 |
20110044997 | METHODS - The current invention provides a method for mobilising endothelial progenitor cells (EPC) and/or mesenchymal stem cells (MSC) in a patient, wherein the method comprises the steps of (i) administering a vascular endothelial growth factor receptor (VEGFR) agonist to the patient; and (ii) administering an antagonist of CXCR4 to the patient. Also provided are uses of EPC and MSC harvested using the methods of the invention. | 2011-02-24 |
20110044998 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof - Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided. | 2011-02-24 |
20110044999 | IL-32 MODULATORS - The present invention relates to methods of screening for modulators of interleukin 32 (IL-32), to modulators of IL-32 and to their use. | 2011-02-24 |
20110045000 | Anti-GM-CSF antibodies and uses therefor - The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 2011-02-24 |
20110045001 | Transfection results of non-viral gene delivery systems by influencing of the innate immune system - The innate immune system of eukaryotes is able to recognise foreign genetic material by means of Toll-like receptors and to initiate signal transduction cascades that trigger an antiviral state of cell populations by way of an interferon response. That antiviral state is also a barrier for non-viral gene delivery systems. If the signal transduction cascade is interrupted intracellularly or intercellularly, transfection efficiencies of non-viral gene delivery systems can be increased and undesirable changes in the expression profile can be avoided. Since RNA-interference is to be attributed to the antiviral state, the RNAi machinery is likewise activated after activation of the innate immune system. In that way, knock-down efficiencies on transfection with siRNA can be increased. | 2011-02-24 |
20110045002 | METHODS OF MODULATING IMMUNE RESPONSES BY MODULATING TIM-1, TIM-2 AND TIM-4 FUNCTION - The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them. | 2011-02-24 |
20110045003 | CADHERIN-11 ANTAGONISTS AND METHODS FOR THE TREATMENT OF INFLAMMATORY JOINT DISORDERS - The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumatoid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist. | 2011-02-24 |
20110045004 | METHOD FOR IN-VITRO DETECTING PATHOGENIC T HELPER CELLS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES - The invention relates to a method for in-vitro detecting pathogenic T helper cells by incubating a sample of a body fluid or tissue taken from a mammal with substances specifically interacting with at least one gene product encoded by selected genes, which are differentially expressed compared to normal T helper cells, determining specific incubation products, correlating an amount of signal or change in signal with a concentration of the gene product in the sample, and detecting cell pathogenicity by comparing the concentration with another gene product concentration in a sample of non-pathogenic and/or pathogenic cells. Another object if the invention concerns a pharmaceutical composition for prophylaxis and therapy of chronicinflammatory. The invention also relates to a method for screening substances with the property to reduce the pathogenicity of T helper cells along with the symptoms of chronic inflammatory diseases. | 2011-02-24 |
20110045005 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2011-02-24 |
20110045006 | LUCA2 and Antibodies That Bind Thereto - The invention provides the identification and characterization of disease and cancer-associated antigen, LUCA2. The invention also provides a family of monoclonal antibodies that bind to antigen LUCA2, methods of diagnosing and treating various human cancers and diseases that express LUCA2. | 2011-02-24 |
20110045007 | FUSION OR LINKED PROTEINS WITH EXTENDED HALF LIFE - The present invention provides fusion proteins comprising a first molecule, and a second molecule which is a monovalent immunoglobulin or a fragment of a monovalent immunoglobulin with a long half-life when administered in vivo, methods of making such fusion proteins, pharmaceutical compositions comprising such fusion proteins, and uses thereof. | 2011-02-24 |
20110045008 | THERAPEUTIC AGENTS FOR INDUCING PLATELET FRAGMENTATION AND TREATING THROMBOEMBOLIC DISORDERS - The present invention is directed to a therapeutic agent comprising a GPIIIa(49-66) specific targeting agent and a thrombi-specific homing agent. Also disclosed is the use of the therapeutic agent in carrying out a method of treating thromboembolic disorders and a method of inducing platelet fragmentation. | 2011-02-24 |
20110045009 | Cell Permeable Peptide - The number of peptides having an ability to bind to a cell or penetrate into a cell is narrowed down by being selectively enriched from a random peptide library with a diversity of not less than one hundred millions of peptides using a phage surface display technique, and then cytoplasmic transfer is evaluated by using protein synthesis inhibition as an indicator by adding to a cell, a fusion body of the selectively enriched peptide and a protein synthesis inhibitory factor (PSIF) that cannot solely penetrate into the cell. | 2011-02-24 |
20110045010 | ANTI-LPS FACTOR FROM PARIETARIA JUDAICA AND METHODS OF USE THEREOF - The present invention falls within the field of molecular biology, and in particular it refers to peptides, polypeptides, protein molecules, uses, methods, processes, systems and compositions for minimizing the presence of molecules in a material and/or interfering with effects associated to such molecules. In particular, the present invention can appear in the form of anti-septic shock pharmacological composition and systems of purification from bacterial endotoxins. | 2011-02-24 |
20110045011 | TRUNCATED RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN ANTIGEN (R56) OF ORIENTIA TSUTSUGAMUSHI STRAINS KARP, KATO and GILLIAM AND ITS USE IN ANTIBODY BASED DETECTION ASSAYS AND VACCINES - A recombinant, refolded non-fusion polypeptide expressed from a truncated r56 gene of the causative agent of scrub typhus, | 2011-02-24 |
20110045012 | ANTI-ATHEROMA VACCINE - The invention relates to a recombinant protein comprising: a carrier portion; a first epitope capable of eliciting an anti-atheroma response; and a second epitope capable of eliciting an anti-atheroma response, characterised in that said first and second epitopes are distinct from one another. | 2011-02-24 |
20110045013 | CAT Allergen Conjugates and Uses Thereof - The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens. | 2011-02-24 |
20110045014 | ACCELERATION AGENT OF CALCIUM ABSORPTION - The present invention provides an accelerating agent for calcium absorption comprising Gum Arabic, which is daily available while simultaneously taking dietary fiber. | 2011-02-24 |
20110045015 | CONJUGATED BETA-1,3-LINKED GLUCANS - Glucans having exclusively or mainly β-1,3 linkages are used as immunogens. These comprise β-1,3-linked glucose residues. Optionally, they may include β-1,6-linked glucose residues, provided that the ratio of β-1,3-linked residues to β-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by β-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolysed to a suitable form prior to conjugation. | 2011-02-24 |
20110045016 | UTILIZATION OF RECOMBINANT INFLUENZA VIRUSES AND MODIFIED VACCINIA ANKARA VIRUS (MVA) WITH GENES THAT ENCODE FOR THE TOXOPLASMA GONDII SAG1 AND SAG2 SURFACE PROTEINS, AS VACCINES AGAINST TOXOPLASMOSIS - The present invention concerns to recombinant influenza viruses and modified Vaccinia Ankara viruses (MVA), and to a process for construction of recombinant influenza viruses and modified vaccinia Ankara viruses (MVA) with genes that encode for the | 2011-02-24 |
20110045017 | HIV VACCINE FOR MUCOSAL DELIVERY - This invention is directed to pharmaceutical compositions comprising an HIV antigen and a mucosal adjuvant and methods for raising an immune response in a subject by administering these compositions. Preferably, the pharmaceutical compositions of the invention can be used to treat or prevent HIV infection. | 2011-02-24 |
20110045018 | ASTROVIRUS SPECIES - Provided herein are sequences of the genomes and encoded proteins of new astrovirus species, and variants thereof. Also provided are methods of detecting the new astrovirus species and diagnosing astrovirus infection, methods of treating or preventing astrovirus infection, and methods for identifying anti-astrovirus compounds. | 2011-02-24 |
20110045019 | PORCINE TORQUE TENO VIRUS VACCINES AND DIAGNOSIS - The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine Torque teno virus (PTTV) genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA. The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same. The present invention further provides live, attenuated, vector-expressed and purified recombinant capsid subunit or killed viral vaccines for protection against PTTV infection. The present invention additionally provides subunit vaccines comprising PTTV specific gene products, especially ORF1 capsid gene product for protection against PTTV infection. Further, the present invention provides methods for diagnosing PTTV infection via polymerase chain reaction (PCR) using specific primer for PTTV1, PTTV2, and individual PTTV1 genotypes. Finally, the present invention provides methods for diagnosing PTTV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies. | 2011-02-24 |
20110045020 | NUCLEIC ACID COMPRISING CHIMERIC GENE DERIVED FROM HEPATITIS C VIRUS - This invention provides infectious chimeric HCV particles that can be used for vaccines. This invention further provides a nucleic acid comprising a chimeric gene derived from the hepatitis C virus comprising regions each encoding Core protein, E1 protein, E2 protein and p7 protein derived from a hepatitis C virus strain other than JFH-1 strain; NS2 protein derived from JFH-1 strain or a hepatitis C virus strain other than JFH-1 strain, or a chimeric NS2 protein of NS2 protein derived from JFH-1 strain and NS2 protein derived from a hepatitis C virus strain other than JFH-1 strain; and NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein derived from JFH-1 strain in that order in 5′ to 3′ direction, wherein the 328th proline residue from the amino acid residue at N-terminus of the Core protein is substituted with an amino acid residue other than proline. This invention further provides chimeric HCV particles comprising such nucleic acid, and use of such HCV particles for vaccines. | 2011-02-24 |
20110045021 | SUGAR IMMUNOGENS - Disclosed are compositions and methods useful for inducing an immunogenic response in a subject or host. In particular, the compositions and methods may be directed to carbohydrate HIV vaccines and to methods of producing a carbohydrate HIV vaccine by introducing antigenic sugars into mimics of the glycans of the HIV envelope glycoproteins gp120 and gp41. | 2011-02-24 |
20110045022 | VACCINES INCLUDING ANTIGEN FROM FOUR STRAINS OF INFLUENZA VIRUS - Vaccines of the invention include at least four influenza virus strains. In some embodiments, the vaccines are produced in cell culture rather than in eggs. In some embodiments, the vaccines include an adjuvant. In some embodiments, the vaccines are not split or whole virion vaccines, but are live or purified glycoprotein vaccines. In some embodiments, the vaccines contain substantially the same mass of hemagglutinin (HA) for each of the influenza virus strains. In some embodiments, the four strains will include two influenza A virus strains and two influenza B virus strains (‘A-A-B-B’). In other embodiments, the four strains will include three influenza A virus strains and one influenza B virus strain (‘A-A-A-B’). | 2011-02-24 |
20110045023 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 2011-02-24 |
20110045024 | RNA VIRUS VACCINES AND METHODS - The invention is a vaccine, and method of vaccination, against RNA viruses, including RNA viruses in the family Flaviviridae, which includes for example West Nile Virus, Yellow fever virus, Dengue fever virus, Hepatitis C virus, Pestiviruses, Bovine viral diarrhea virus, and Classical Swine fever virus, wherein the vaccine comprises the RNA virus or immunogenic portions thereof, which have been treated with and rendered non-pathogenic by a phenothiazine dye and visible light. The invention includes novel strains of WNV for use in producing a vaccine. | 2011-02-24 |
20110045025 | Pharmaceutical Compositions Containing Clostridium Difficile Toxoids A and B - This invention relates to compositions including | 2011-02-24 |
20110045026 | PRODUCTION OF FUNGAL EXTRACELLULAR IMMUNE STIMULATING COMPOUNDS - A process is described for the production of an immunostimulant by submerged cultivation of | 2011-02-24 |
20110045027 | Adjuvant - The present invention provides a novel adjuvant for polynucleotide vaccines, and in particular the present invention provides immunogenic compositions comprising a polynucleotide encoding an antigen capable of eliciting an immune response and an adjuvant comprising an immunostimulatory quantity of a gemini surfactant, or a derivative thereof. | 2011-02-24 |
20110045028 | SUSTAINED RELEASE PREPARATION - Disclosed is a sustained-release preparation which is prepared by shaping a granule comprising a blood coagulation factor Xa inhibitor and a mixture of at least two hydrophilic polymers. Also disclosed is a pharmaceutical composition comprising a combination of the sustained-release preparation and an immediate release preparation comprising a blood coagulation factor Xa inhibitor. It becomes possible to provide a controlled release preparation comprising a blood coagulation factor Xa inhibitor for the prevention or treatment of thrombosis, which can control the activity of blood coagulation factor Xa for a long term and is excellent in convenience and compliance. It is also becomes possible to provide a method for producing the controlled release preparation. | 2011-02-24 |
20110045029 | ORAL FORMULATION FOR DELIVERY OF POORLY ABSORBED DRUGS - A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone). | 2011-02-24 |